Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Tamer OthmanAlex HerreraMatthew G MeiPublished in: Current hematologic malignancy reports (2021)
Investigators have explored methods with the potential to restore sensitivity to BV and CPIs in patients who develop resistance. Additionally, promising new therapeutics are emerging, such as CD25-directed ADC therapy and CD30-directed chimeric antigen receptor (CAR) T cells. While no consensus guidelines exist for the management of HL patients refractory to BV and checkpoint blockade, potential novel strategies and therapeutics are currently under investigation in hopes of expanding the treatment landscape for this challenging patient population.
Keyphrases
- hodgkin lymphoma
- end stage renal disease
- small molecule
- lps induced
- ejection fraction
- lipopolysaccharide induced
- newly diagnosed
- dna damage
- chronic kidney disease
- clinical practice
- prognostic factors
- risk assessment
- acute myeloid leukemia
- cell cycle
- nk cells
- peritoneal dialysis
- patient reported outcomes
- single cell
- inflammatory response
- computed tomography
- bone marrow
- magnetic resonance imaging
- diffuse large b cell lymphoma
- climate change